VERTEX PHARMACEUTICALS INC / MA (VRTX) Form 8-K — Jul 6, 2026
$VRTXForm 8-KItems 1.01, 7.01, 8.01, 9.01Filed Jul 6, 2026, 9:55 PM ET0001193125-26-296710Original filing
Vertex Pharmaceuticals entered into a definitive agreement to acquire Crinetics Pharmaceuticals for $85.00 per share in cash, representing an equity value of approximately $10 billion. The transaction adds a new Endocrine pillar to Vertex's portfolio, including the approved therapy PALSONIFY for acromegaly and the late-stage candidate atumelnant for congenital adrenal hyperplasia, with a combined peak sales potential of over $5 billion.
Key figures
- Debt Amount
- 4,500,000,000
- Deal Value Usd
- 10,000,000,000
- Price per share
- 85.00
- Termination fee
- 350,474,425
- Net of cash value
- 8,800,000,000
- Peak sales potential
- >5,000,000,000
Price after filing
1 day: -1.4%7 days: -9.3%30 days: -9.6%
Close on the filing date to close N calendar days later (from $529.59). Historical, not a forecast.
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.